搜尋結果
2024年5月10日 · Comirnaty Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. The use of this vaccine should be in
2024年5月3日 · At T1, only 13 (12.1%) and 2 (1.9%) participants had detectable NAbs against D614G and Omicron BA.5, while no detectable NAb titers against Omicron XBB.1.5, BA.2.86, and JN.1 were observed in the serum of all elderly participants.
2024年5月22日 · Omicron最新亞型變異株BA.2.75在印度迅速傳播。. （美聯社）. 新冠病毒變種速度不斷加快，Omicron另一迅速傳播的亞型變異株BA.2.75，再度引發病毒學家憂心，指出BA.2.75的關鍵突變，可能導致此前接種疫苗的保護力大幅降低。. BA.2.75目前在印度迅速傳播，英國近期也 ...
COVID-19 Variant Update. 14 May, 2024. As of May 14, 2024, the SARS-CoV-2 Omicron variants JN.1 and a JN.1 descendant, KP.2, have high prevalence in the United States. CDC Nowcast projections estimate KP.2 (also called JN.1.11.1.2), to account for nearly 30% of new COVID-19 illnesses in the U.S.
2024年5月15日 · When administered as a 2-dose primary series or a booster, the omicron BA.1 variant-containing COVID-19 vaccine (mRNA-1273.214) is immunogenic against BA.1 and D614G in children aged 6 months to 5 years, with a safety profile comparable to mRNA-1273, according to study results published in The Lancet. Researchers conducted an open-label, 2 ...
2024年5月8日 · In this study, 50 participants received Spikevax XBB.1.5 and 51 participants received an investigational Omicron bivalent XBB.1.5/BA.4-5 vaccine (0.5 mL, 25 micrograms/25 micrograms). The vaccines were administered as a fifth dose to adults who previously received a two-dose primary series and a booster dose of an original mRNA COVID-19 vaccine, and a booster dose of a bivalent Original ...
2024年5月1日 · JN.1 เป นสายพ นธ ล กของโอไมครอน BA.2.86 ท กลายพ นธ ตำแหน ง L455S และ JN.1 เองเก ดการกลายพ นธ เพ มเต มท ตำแหน ง F456L และ R346T กลายเป นสายพ นธ ย อยช อ KP.2 นอกจากน JN.1 ย งกลายพ นธ อ ...
